Summary
Arterial hypertension has been identified as a major secondary risk factor for diabetic retinopathy. However, the mechanisms by which hypertension worsens retinopathy are unknown. Inhibition of advanced glycation product formation prevents the development of experimental diabetic retinopathy in normotensive diabetic rats. In this study the effect of hypertension on the rate of diabetic retinopathy development and the formation of arteriolar thrombosis was evaluated. We also evaluated the effect of aminoguanidine, an inhibitor of advanced glycation end product formation on retinal pathology of diabetic hypertensive rats. After 26 weeks of diabetes, hypertension accelerated the development of retinopathy despite a lower mean blood glucose level than in the non-hypertensive group (diabetic spontaneous hypertensive rats (SHR) 16.00±6.83 mmol/l; diabetic normotensive Wistar Kyoto rats (WKY) 34.9±3.64 mmol/l; p<0.0001). Diabetic SHR had nearly twice as many acellular capillaries as diabetic WKY (SHR diabetic: 91.9±7.5 acellular capillaries per mm2 of retinal area vs WKY diabetic: 53.7±8.5 acellular capillaries per mm2 of retinal area), and a 3.8-fold increase in the number of arteriolar microthromboses (SHR diabetic 23504±5523 μm2 vs SHR non-diabetic 6228±2707 μm2). Aminoguanidine treatment of SHR diabetic rats reduced the number of acellular capillaries by 50%, and completely prevented both arteriolar deposition of PAS-positive material and abnormal microthrombus formation. These data suggest that hypertension-induced deposition of glycated proteins in the retinal vasculature plays a central role in the acceleration of diabetic retinopathy by hypertension.
Article PDF
Similar content being viewed by others
References
Krolewski A, Canessa M, Warram JH et al. (1988) Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 318: 140–146
Klein R, Klein BED, Moss SE, Davis MD, DeMets DL (1989) Is blood pressure a predictor of the incidence or progression of diabetic retinopathy·? Arch Intern Med 149: 2427–2432
Drury PL (1983) Diabetes and arterial hypertension. Diabetologia 24: 1–9
Mathiesen ER, Hommel E, Giese J, Parving H-H (1991) Efficacy of Captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303: 81–87
Teuscher A, Schnell H, Wilson PWF et al. (1988) Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 11: 246–251
Knowler WC, Bennett PH, Ballintine EJ (1980) Increased incidence of retinopathy in diabetics with elevated blood pressure. N Engl J Med 302: 645–650
Pisu E, Vitelli F, Coggi G et al. (1988) Univariate and multivariate analysis of associated factors of retinopathy in 894 Italian adult diabetics. Diabete Metab 14: 700–705
Duane TD, Thomas B, Field RA (1969) Symp treat diabetic retinopathy. USPHS publication 1890, Arlington, VA, GPO 657–663
Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555–11558
Esposito C, Gerlach H, Brett J, Stern D, Vlassara H (1989) Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170: 1387–1407
Edelstein D, Brownlee M (1992) Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35: 96–97
Kuwabara T, Cogan M (1960) Studies of retinal vascular pattern. I.Normal architecture. Arch Ophthalmol 64: 904–911
Engerman RL, Kern TS (1987) Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36: 808–812
Sachs L (1992) Angewandte Statistik. 7th edn. Springer, Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest
Robison WG Jr, McCaleb ML, Feld LG, Michaelis OE, Laver N, Mercandetti M (1991) Degenerated intramural pericytes (’ghost cells’) in the retinal capillaries of diabetic rats. Curr Eye Res 10: 339–350
Brownlee M, Cerami A (1981) The biochemistry of diabetic complications. Annu Rev Biochem 50: 385–432
Panagiotopoulos S, Gin T, Joon T et al. (1992) Antihypertensive therapy ameliorates increased albumin permeation in hypertensive diabetic rats: contrasting effects in the retina and kidney. Diabetes 41 (Suppl 1): 19 (Abstract)
Garner A, Ashton N, Tripathi R, Kohner EM, Bulpitt CJ, Dollery CT (1975) Pathogenesis of hypertensive retinopathy. An experimental study in the monkey. Br J Ophthamol 59 (1): 3–44
Hayreh SS, Servais GE, Virdi PS (1989) Retinal arteriolar changes in malignant arterial hypertension. Ophthalmol 198: 178–196
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Giambrone SA (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 83: 4533–4537
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hammes, H.P., Brownlee, M., Edelstein, D. et al. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37, 32–35 (1994). https://doi.org/10.1007/BF00428774
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00428774